Search results for " Epidermal Growth Factor"

showing 8 items of 38 documents

Synthesis of Triazenoazaindoles: a New Class of Triazenes with Antitumor Activity

2011

Despite improvements in the treatment and prevention of cancer, the number of new diagnoses continues to rise; this has fuelled substantial interest in the development of new and effective chemotherapeutic agents. Compounds of the triazene class, such as dacarbazine, have been used in the clinical management of many cancer types including brain, leukemia, and melanoma. A new compound class bearing a triazenoazaindole scaffold was synthesized with the aim of identifying new antiproliferative agents. Compounds 5 a-g and 6 a-c were screened against a panel of human tumor cell lines, and two of them, 5 e and 5 f, showed cytotoxicity (GI(50) range: 2.2-8.2 μM) in all cell lines. These two compou…

Programmed cell deathIndolesToxicology and Pharmaceutics (all)DacarbazineAntineoplastic AgentsAntiproliferative activityPharmacologyEGF receptorsDrug Screening AssaysBiochemistryCell LineFlow cytometryCell Line TumorNeoplasmsDrug DiscoveryTriazenoazaindolemedicineHumansTriazeno derivativesGeneral Pharmacology Toxicology and PharmaceuticsCytotoxicityPharmacologyAntitumor agentsTumorEpidermal Growth Factormedicine.diagnostic_testChemistryMelanomaOrganic ChemistryCancerAntitumorTriazenoazaindoles; Dacarbazine; Antitumor Activitymedicine.diseaseErbB ReceptorsDacarbazineApoptosisCell cultureMolecular MedicineDrug Screening Assays AntitumorAntitumor ActivityTriazenesTriazenoazaindolesAntiproliferative activity; Antitumor agents; EGF receptors; Triazeno derivatives; Antineoplastic Agents; Cell Line Tumor; Dacarbazine; Drug Screening Assays Antitumor; Humans; Indoles; Neoplasms; Receptor Epidermal Growth Factor; Triazenes; Pharmacology Toxicology and Pharmaceutics (all); Organic Chemistry; Molecular MedicineReceptormedicine.drugChemMedChem
researchProduct

The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway

2010

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with metastatic colorectal carcinoma. Among patients not carrying activating mutations in the KRAS gene, only a limited number will experience tumor response to these therapeutic agents. The role of BRAF mutations in determining resistance to this treatment is emerging through preclinical and clinical studies. Standardization and validation of laboratory mutation analysis is needed to allow an optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Clinical single-arm and randomized studies were conducted both in first-line and refractory settings to evaluate…

Proto-Oncogene Proteins B-rafCancer ResearchPrognosiColorectal cancerCetuximabColorectal Neoplasmmedicine.disease_causeBRAFProto-Oncogene Proteins p21(ras)FOLFOXProto-Oncogene ProteinsAntineoplastic Combined Chemotherapy ProtocolsKRASmedicineHumansPanitumumabEpidermal growth factor receptorBRAF; Cetuximab; Colorectal carcinoma; KRAS; Panitumumab; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Receptor Epidermal Growth Factor; Signal Transduction; ras Proteins; Cancer Research; OncologyneoplasmsProto-Oncogene ProteinClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolCetuximabbiologybusiness.industryPanitumumabGeneral Medicineras ProteinPrognosismedicine.diseasedigestive system diseasesOxaliplatinErbB ReceptorsColorectal carcinomaOncologyMutationras ProteinsCancer researchFOLFIRIbiology.proteinReceptor Epidermal Growth FactorKRASPredictive factorColorectal NeoplasmsbusinessHumanSignal Transductionmedicine.drugOncology
researchProduct

Age-dependent regulation of antioxidant genes by p38α MAPK in the liver

2018

p38α is a redox sensitive MAPK activated by pro-inflammatory cytokines and environmental, genotoxic and endoplasmic reticulum stresses. The aim of this work was to assess whether p38α controls the antioxidant defense in the liver, and if so, to elucidate the mechanism(s) involved and the age-related changes. For this purpose, we used liver-specific p38α-deficient mice at two different ages: young-mice (4 months-old) and old-mice (24 months-old). The liver of young p38α knock-out mice exhibited a decrease in GSH levels and an increase in GSSG/GSH ratio and malondialdehyde levels. However, old mice deficient in p38α had higher hepatic GSH levels and lower GSSG/GSH ratio than young p38α knock-…

ROS Reactive oxygen species;RSK1 Ribosomal S6 kinase10301 basic medicineMAPK/ERK pathwayAgingHPLC High-performance liquid chromatographyAntioxidantmedicine.medical_treatmentTBP TATA-binding proteinClinical BiochemistryDEN Diethyl nitrosamine;MKP-1 MAPK phosphatase-1IκB kinaseGCLc Glutamate cysteine ligase catalytic subunitp38 Mitogen-Activated Protein KinasesG6PDH Glucose-6-phosphate dehydrogenaseBiochemistryAntioxidantsMicechemistry.chemical_compoundSuperoxide Dismutase-1Akt Protein kinase B0302 clinical medicineNrf2 Nuclear factor erythroid 2-related factor-2IL InterleukinSOD1 Cu/Zn-superoxide dismutaselcsh:QH301-705.5Mice KnockoutMK2 MAP-activated protein kinase 2;PGC-1α Peroxisome proliferator-activated receptor gamma coactivator 1-alphachemistry.chemical_classificationlcsh:R5-920Trx ThioredoxinGlutathione DisulfideTNF-α Tumor necrosis factor-alphabiologyLPS Lipopolysaccharide;GSSG Oxidized glutathione;MEF Mouse embryonic fibroblastsNF-kappa BGstm1 Glutathione S-transferase mu 1CatalaseEndoplasmic Reticulum StressGlutathioneLiverGSH Reduced glutathione;Catalase030220 oncology & carcinogenesisJNK c-Jun N-terminal kinaselcsh:Medicine (General)Research Papermedicine.medical_specialtyNF-E2-Related Factor 2Glutamate-Cysteine LigaseMKK MAPK kinaseAP-1 Activator protein-1IKK IƙB KinaseGene Expression Regulation EnzymologicSuperoxide dismutase03 medical and health sciencesInternal medicineGlutamate cysteine ligaseEGFR Epidermal growth factor receptormedicineAnimalsNuclear factor ƙBAnd catalaseChIP Chromatin immunoprecipitation;Protein kinase BNF-ƙB Nuclear factor kappa BSuperoxide DismutaseSuperoxide dismutase 1Superoxide dismutase 2Organic ChemistryGlutathioneASK1 Apoptosis signal-regulating kinase 1ATF2 activating transcription factor 2;030104 developmental biologyEndocrinologyEnzymeHsp Heat shock proteinlcsh:Biology (General)chemistrybiology.proteinSOD2 Mn-superoxide dismutaseMAPK mitogen activated protein kinaseNEM N-ethyl maleimide;Redox Biology
researchProduct

Caveolin-1, breast cancer and ionizing radiation

2015

Breast cancer (BC) recovery has increased in recent years thanks to efforts of Omics-based research in this field. However, despite the important results obtained, BC remains a complex multifactorial pathology that is difficult to treat appropriately. Caveolin-1 (CAV1), the basic constituent protein of specialized plasma membrane invaginations called caveolae, is emerging as a potential therapeutic biomarker in BC. This factor may modulate BC response to chemotherapy and radiation therapy. In addition, recent reports describe the key role of CAV1 during cell response to oxidative stress. The aim of the present review was to describe the biological roles of CAV1 in BC considering its contras…

RadiotherapyAnimalCAV1; biomarker; breast cancer; ionizing radiation; review; Animals; Biomarkers Tumor; Breast Neoplasms; Caveolin 1; Cell Transformation Neoplastic; Female; Gene Expression Regulation Neoplastic; Humans; Molecular Targeted Therapy; Radiotherapy; Receptor Epidermal Growth Factor; Radiation IonizingCaveolin 1reviewBreast NeoplasmsErbB ReceptorsGene Expression Regulation Neoplasticbreast cancerCell Transformation NeoplasticCAV1Radiation IonizingBiomarkers TumorAnimalsHumansbiomarkerFemaleMolecular Targeted TherapyReceptor Epidermal Growth Factorionizing radiationBreast NeoplasmHuman
researchProduct

Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules

2011

The treatment of solid malignancies includes various target drugs, such as monoclonal antibodies and tyrosine kinase inhibitors, which exert their effect alone or in combination with chemotherapy. The main part of these molecules have a target on proteins of EGFR and VEGF pathways. The particular toxicity profile and the financial impact, deriving from the application of these agents in cancer treatment, prompted a lot of researches to define predictive factors of their efficacy. Various biomarker were identified among the components of the targeted pathways. However just few studies allowed to identify specific factors to predict the toxicity of these drugs. In this review EGFR and VEGF-re…

Vascular Endothelial Growth Factor Amedicine.drug_classSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryAngiogenesis InhibitorsAntineoplastic AgentsPharmacologyMonoclonal antibodyTargeted therapyAntineoplastic AgentNeoplasmsProtein-Tyrosine KinasemedicineHumansAngiogenesis Inhibitors; Antibodies Monoclonal; Antineoplastic Agents; Humans; Neoplasms; Protein-Tyrosine Kinases; Receptor Epidermal Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor ATarget therapyPharmacologyAnti vegfChemotherapybusiness.industryAntibodies MonoclonalProtein-Tyrosine KinasesErbB ReceptorsTreatment OutcomeToxicityCancer researchBiomarker (medicine)NeoplasmReceptor Epidermal Growth FactorbusinessTyrosine kinaseAngiogenesis InhibitorHuman
researchProduct

Molecular Subtypes, Metastatic Pattern and Patient Age in Breast Cancer: An Analysis of Italian Network of Cancer Registries (AIRTUM) Data

2021

Breast cancer stage at diagnosis, patient age and molecular tumor subtype influence disease progression. The aim of this study was to analyze the relationships between these factors and survival in breast cancer patients among the Italian population using data from the AIRTUM national database. We enrolled women with primary breast cancer from 17 population-based cancer registries. Patients were subdivided into older (>69 years), middle (50–69 years) and younger age groups (<50 years) and their primary tumors categorized into four molecular subtypes based on hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. There were 8831 patients diagnosed betwe…

hormone receptor (HR)Rhormone receptor (HR); human epidermal growth factor receptor 2 (HER2); breast cancer; metastasis; age; population-based; cancer registryGeneral MedicineSettore MED/42 - Igiene Generale E ApplicataArticleAge Breast cancer Cancer registry Hormone receptor (HR) Human epidermal growth factor receptor 2 (HER2) Metastasis Population‐basedpopulation-basedbreast cancerhuman epidermal growth factor receptor 2 (HER2)agecancer registrymetastasisMedicineJournal of Clinical Medicine; Volume 10; Issue 24; Pages: 5873
researchProduct

Optimized culture conditions for tissue explants of uterine leiomyoma

2012

Background Uterine leiomyomas are the most common benign tumours in women, which arise from smooth muscle cells of the uterine myometrium and usually are multicentric. In spite of their frequency pathogenesis is widely unknown, mainly due to the absence of a suitable model system. We describe the systematic optimization of culturing leiomyoma tissue explants in an economical and effective ex vivo system. Methods Different concentrations of oxygen, different media, sera, hormones, and growth factor supplements were tested. Immunohistochemical stainings with antibodies against hormone receptors as well as specifying proliferation and apoptotic indices and real-time PCR were performed. Results…

medicine.medical_treatmentCulture Media; Epidermal Growth Factor; Estradiol; Female; Humans; Immunohistochemistry; Leiomyoma; Progesterone; RNA Messenger; Real-Time Polymerase Chain Reaction; Uterine NeoplasmsBiologyReal-Time Polymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyAndrologyTissue culturemedicineHumansRNA MessengerUterine NeoplasmProgesteroneUterine leiomyomaEpidermal Growth FactorEstradiolLeiomyomaGrowth factorMyometriummedicine.diseaseImmunohistochemistrySettore MED/40 - Ginecologia E OstetriciaCulture MediaLeiomyomaHormone receptorUterine NeoplasmsFemaleEx vivoHuman
researchProduct

Trastuzumab-emtansine induced pleural and pericardial effusions

2021

Introduction Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate which combine trastuzumab (T), a monoclonal antibody targeting the human epidermal growth factor receptor-2 (HER2), and a cytotoxic molecule derived from maytansine (DM1). Case report We report the first case of T-DM1-associated pleural and pericardial effusions three weeks after the second course of T-DM1 in a patient with breast cancer. Drug-induced pleural and pericardial effusions was implicated in the absence of other etiologies. The Naranjo Scale indicated a probable drug-induced adverse reaction. Management & outcome: The patient fully recovered after thoracentesis and discontinuation of T-DM1. The patient h…

musculoskeletal diseasesReceptor ErbB-2medicine.drug_classBreast NeoplasmsAdo-Trastuzumab EmtansineAntibodies Monoclonal HumanizedMonoclonal antibodyPericardial effusionPericardial Effusion03 medical and health scienceschemistry.chemical_compound0302 clinical medicineTrastuzumabmedicineHumansMaytansinePharmacology (medical)business.industryHuman epidermal growth factorTrastuzumabmedicine.diseaseOncologychemistryTrastuzumab emtansine030220 oncology & carcinogenesisCancer researchFemalebusiness030215 immunologymedicine.drugConjugateJournal of Oncology Pharmacy Practice
researchProduct